36 results on '"Symanowski, James T."'
Search Results
2. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
3. Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis
4. Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites
5. Single-Fraction Stereotactic Radiosurgery (SRS) Alone Versus Surgical Resection and SRS for Large Brain Metastases: A Multi-institutional Analysis
6. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials
7. External Validity of a Risk Stratification Score Predicting Early Distant Brain Failure and Salvage Whole Brain Radiation Therapy After Stereotactic Radiosurgery for Brain Metastases
8. Breast cancer detection in axillary sentinel lymph nodes: the impact of the method of pathologic examination
9. A retrospective analysis of the clinical performance of human papillomavirus testing using SurePath sample collection
10. Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
11. Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation
12. Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer
13. Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate Cancer
14. Acquired Immunity in Patients with Multiple Myeloma Undergoing Maintenance Therapy Post-Autologous Hematopoietic Cell Transplantation
15. Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience
16. Impact of Polymorphisms in Pharmacokinetic Genes on Tyrosine Kinase Inhibitor (TKI) Tolerability in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
17. Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
18. Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia
19. Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma
20. Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
21. Favorable Survival Outcomes in Acute Myeloid Leukemia (AML) Patients (pts) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) without Achieving Complete Remission (CR) to Non-Intensive Chemotherapy
22. Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)
23. Patient Reported Financial Toxicity in Acute Leukemia
24. Survival and Time to Response with Frontline Hypomethylating Agents in AML
25. Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis
26. Higher Incidence of Hemorrhagic Cystitis after Haploidentical Compared to Matched Sibling Donor Transplantation
27. Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
28. Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma
29. Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplantation Program
30. CYP2C19 Genotype-Guided Dosing and Voriconazole Concentrations in Hematopoietic Stem Cell Transplant Patients (HSCT) Receiving Antifungal Prophylaxis
31. Outcomes in Transplant Eligible Multiple Myeloma African American Patients Appear Similar to Caucasian Patients
32. Fluorescence in Situ Hybridization (FISH) abnormalities and Baseline Clinical Features at Diagnosis in African American Multiple Myeloma Patients
33. Cost-Effectiveness of Pemetrexed Plus Cisplatin: Malignant Pleural Mesothelioma Treatment in UK Clinical Practice
34. Usefulness of BMI and the novel concept of skin to fascia length (STFL) in predicting length of stay (LOS), readmission, and complications following radical cystectomy (RC)
35. It matters: day of week (DOW) and type of surgical assistant (SAT) (second attending [SA] vs fourth year resident [R-4] vs advanced care provider [ACP]) predict outcomes following radical cystectomy
36. Do early postoperative lactic acid (LA) levels predict adverse outcomes after cystectomy?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.